Thndr Claps
  • U.S.
  • Egypt
  • Saudi
  • Thinkers
  • Arabic
No Result
View All Result
Thndr Claps

Thndr Claps » U.S. Claps » Health & Pharma💉 » CVS beats Q3 estimates 💊

CVS beats Q3 estimates 💊

by Omar El Shorafa
November 3, 2022
Claps

The Clap
CVS Health (NYSE: CVS) recorded an EPS of $2.09 and revenue of $81.16 billion, beating analysts’ expectations on both the top and bottom lines.

The Deets
Revenue saw a 10% increase YoY. This quarter’s earnings mark the 3rd consecutive quarter that the company beat earnings expectations.

After topping estimates, the company increased its full-year outlook, with an estimated EPS range of $8.55 to $8.65.

So What
The company’s shares jumped more than 2% following the news.

Related News
CVS acquired Signify for $8 billion in September, the first step in the expansion into the at-home healthcare sector.

  • Click to share on Facebook (Opens in new window)
  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)

Related Posts

Claps, Health
Tech 📲

Amazon offer medical subscription service 💊

by Omar El Shorafa
January 25, 2023
Claps, Health
Health & Pharma 💉

BioNTech unfazed by lower profit 💉

by Omar El Shorafa
November 8, 2022
Claps, NYSE, Health & Pharma
Health & Pharma 💉

Pfizer Q3 tops estimates 💉

by Omar El Shorafa
November 2, 2022
Claps, NYSE, Health & Pharma
Health & Pharma 💉

Pfizer to hike vaccine prices 💉

by Omar El Shorafa
October 24, 2022
Claps, NYSE, Health
Health & Pharma 💉

UnitedHealth showed strength in Q3 🚑

by Omar El Shorafa
October 17, 2022
Cano, Claps, NYSE, Health
Health & Pharma 💉

Cano Health could sell 🏥

by Omar El Shorafa
September 26, 2022

Website

Community

Blog

Learn

© Thndr. All rights reserved

No Result
View All Result
  • U.S.
  • Egypt
  • Saudi
  • Thinkers
  • Arabic

Disclaimer: Thndr does not provide investment advice, individual investors are responsible for their own decisions or can seek independent advice. The value of investments can go up and down. Thndr is a trading name of Thndr Securities Brokerage which is authorised and regulated by the Financial Regulatory Authority (FRA). Registered in Egypt (no. 804)..© Thndr. All rights reserved

 

Hello👋 We want you to be able to express your opinions on anything and everything finance and economics related to the Egyptian and US markets.

This is why we introduced Thndr Thinkers💭

Let’s go through some housekeeping notes before you jump into publishing your article to all Thndr Claps readers!

Type of Content📝 We want to see market-relevant content that shows good analysis, please! Base your articles on facts 

Don’t be shy, explain🗣 Flex your knowledge to us, and we’ll share it with all the readers!

Be Original🙏 Please don’t copy. No one likes a copycat. All submissions are welcome as long as they’re yours 

Make your title attractive🤩 A title is like the cover of your book. Attractive enough to make you look at the book but also clear enough to tell you what the book is about.

Clean🧹 We’re all humans and we all make mistakes. But please try and clean up the article so it’s clear for all the readers 

No promotional content🚫 We don’t publish promotional content.

Any questions about becoming a Thndr Thinker? Email thndrclaps@thndr.app and we’d be happy to help!

Normally, your article will be published within 24 hours of submission (if you followed the guidelines)